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MurAA systematic workﬂow consisting of comparative genomics, metabolic pathways analysis and additional drug
prioritization parameters identiﬁed 264 proteins of Vibrio cholerae which were predicted to be absent in Homo
sapiens. Among these, 40 proteins were identiﬁed as essential proteins that could serve as potential drug and
vaccine targets. Additional prioritization parameters characterized 11 proteins as vaccine candidates while
druggability of each of the identiﬁed proteins as evaluated by the Drug Bank database which prioritized 16
proteins suitable for drug targets. As a case study, we built a homologymodel of one of the potential drug targets,
MurA ligase, using MODELLER (9v12) software. The model has been further explored for in silico docking with
inhibitors having druggability potential from the Drug Bank database. Results from this study could facilitate
selecting V. cholerae proteins for drug design and vaccine production pipelines in future.
© 2013 Elsevier Inc. All rights reserved.1. Introduction
Cholera is a severe diarrheal diseasewhich occursmost frequently in
epidemic form, and is caused by the etiological agent, Vibrio cholerae [1].
Over the past 40 years, cholera remains a serious threat in developing
countries where sanitation is poor, health care is limited, and drinking
water is unsafe. Without treatment, the cholera case fatality rate can
be as high as 70% [2].
Like most enteric pathogens, V. cholerae possesses several efﬂux
systems that confer resistance to antibiotics and other cytotoxic drugs
by extruding them from the cell [3]. Spontaneous chromosomal
mutation, conjugative plasmids, SXT elements and integrons also
help to confer drug resistance [4]. Recently, many clinical isolates of
V. cholerae are multidrug resistant [4]. This strongly indicates the need
to search for new therapeutic targets and vaccine candidates that
would offer better protection.
In the present post-genomics era, the possibilities of selecting
targets using computational approaches with integrated “omics” data
such as genomics, proteomics, and metabolomics have been increasing
continuously [5]. Amongst these, two in silicomethods like comparative
and subtractive genomics are being widely used for the prediction and
identiﬁcation of potential drug targets in numerous pathogenic bacteria
[5]. This strategy is based on searching for genes/proteins present in
the pathogen but absent in the host. Furthermore, along with their
non-homologous nature, these genes are essential for the survival of
the pathogen and serve as critical components in vital physiochemical
and metabolic pathways [6].hapatra).
ghts reserved.In the present study, we performed an in silico metabolic pathway
analysis of V. cholerae and its human host for identiﬁcation of therapeu-
tic candidates. It is expected that the identiﬁed potential drug and
vaccine targets will not only expand our understanding on the molecu-
lar mechanisms of V. cholerae pathogenesis but also facilitate the
production of novel therapeutics.2. Results
2.1. Identiﬁcation of metabolic pathways and non-homologous proteins
Using computational comparative and subtractive genomics analysis
of differentmetabolic pathways from V. choleraO1biovar El Tor N16961
(Fig. 1), a list of potential drug and vaccine targets were identiﬁed. We
followed several systematic steps that involved several bioinformatics
tools, databases and drug target prioritization parameters, to obtain
information about proteins that were present in different metabolic
pathways of V. cholerae, but absent in its host, H. sapiens, therefore min-
imizing chances of any side effects [7]. Such proteins are here termed as
‘non-homologous’ proteins. Initial information about the metabolic
pathways of V. cholerae and its human host is obtained from the KEGG
pathway database. At present, KEGG contains information about 100
differentmetabolic pathways of V. cholerae and276metabolic pathways
of H. sapiens. A manual two-list comparative analysis is performed for
the identiﬁcation of pathways unique (present in V. cholerae and not
in H. sapiens) and pathways common to both V. cholerae and its host
H. sapiens. Out of 100 metabolic pathways in V. cholerae, 28 pathways
were found to be unique and 72 pathways were found to be common
between V. cholerae and H. sapiens (Table S1).
Whole genome and proteome of Vibrio cholerae 
Identifying pathway unique to pathogen 
NCBI
+
KEGG 
Identifying genes and mapping of proteins involved in unique pathway to pathogen KEGG
BLAST mapped proteins identified in unique pathway against human proteome NCBI BLASTP
Hits No Hits
Homologous proteins of pathogen 264 non-homologous proteins of the pathogen
Discard
BLAST non-homologous proteins genes against Database of Essential Genes (DEG) NCBI BLASTP + DEG
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E value: 10-10Discard40 essential non-homologous proteins of the pathogen
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Fig. 1. Illustration of predeﬁned comparative and subtractive genomics systemic workﬂow.
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V. cholerae, the next step was to ﬁnd the non-homologous proteins
from the V. cholerae genome. For analysis of such proteins, protein
sequences from common and unique pathways were obtained
and compared using NCBI BLASTP against the human proteome. The
search resulted in identiﬁcation of 264 proteins from unique pathway
that showed no signiﬁcant similarity with the human proteome
(Table S2).2.2. Identiﬁcation of non-homologous essential proteins
In this section, we report the computational identiﬁcation of non-
homologous essential proteins of V. cholerae using the DEG BLASTP
analysis. Identiﬁcation of proteins that are important for its survival,
virulence and pathogenicity, is of great importance for disruption of
pathogen functions. At present, the DEG (Database of Essential Gene)
contains 779 essential genes of V. cholerae [8]. However, it is unknown
how many of these gene products are non-homologous to human
proteins. Not all the essential proteins are non-homologous in nature.
Out of 264 non-homologous proteins, we identiﬁed a total of 40 essen-
tial non-homologous proteins from V. cholerae (Table 1).2.3. Sub-cellular localization and drug target prioritization
Until now, we discussed about non-homologous essential proteins
of the pathogen using computational comparative and subtractive
genomics study. Although this is the major criterion in determining
drug target from a pathogen, several other factors are taken into consid-
eration for suitability of drug and vaccine targets. In our study, we
focused on parameters such as lowmolecular weight of a protein, pres-
ence of transmembrane helices, availability of 3D structures in PDB and
Modbase models and sub-cellular localization of the potential drug and
vaccine targets. Availability of 3D structures helps in docking analysis to
be carried out for novel drug discoveries and should be considered for
future drug design. In silico prediction of sub-cellular localization
provides a quick and inexpensive means for obtaining information
regarding protein function. Cytoplasmic or membrane localization of
the targets determines the ease of puriﬁcation steps to be followed in
experimental studies. It has been considered that proteins with low
molecular weight (100–110 kDa) increase the accessibility value of a
target protein. In our study, out of 40 essential protein targets, 11 are
membrane proteins and rest fall into category of cytoplasmic proteins,
as predicted by CELLO v 2.5 [9] and PSORTb [10] (Table 1). Transmem-
brane predictions were made by using TMHMM [11]. The TMHMM
85P. Chawley et al. / Genomics 103 (2014) 83–93results were almost in agreement with the sub-cellular localization
predictions except two proteins. All these 11 proteins were found to
form antigenic peptide epitopes with cleavage probability ranging
from 0.6234 to 1.00 and MHC binding score ranging from 0.6129 to
0.9118 (Table S3). These scores are better than the threshold score of
0.5.These membrane proteins can act as both drug and vaccine targets
and the remaining proteins can act as drug targets, which can be
exploited for future drug design.
2.4. Druggability of therapeutic targets
Druggability of each of the non-homologous essential proteins of
V. cholerae was identiﬁed by sequence similarity to targets of small
molecule drugs by utilizing the Drug Bank database. This led to the
identiﬁcation of 16 V. cholerae proteins that were highly similar to the
binding partners of FDA-approved and small experimental molecule
drugs (Table S4).
In summary the computational comparative and subtractive genomic/
proteomic analysis of different metabolic pathways resulted in a
step-wise reduction in the number of relevant targets and identiﬁcation
of several proteins of V. cholerae that can be targeted for effective drug
design and vaccine development.
2.5. Pathways unique to V. cholerae when compared to the host H. sapiens
An important question to be addressed while choosing potential
drug targets is whether the biochemical pathway to be targeted is
unique to bacteria [12]. The six pathways unique to pathogen include:
peptidoglycan biosynthesis, D-alanine metabolism, lipo-polysaccharide
biosynthesis, bacterial chemotaxis, bacterial secretion system and
V. cholerae pathogenic cycle.
Amongst these pathways, peptidoglycan biosynthesis and D-alanine
metabolism are common to all bacterial species, and the cell wall bio-
synthetic pathways have long been targeted for antimicrobial discovery.
The lipopolysaccharide (LPS)-rich outer membrane of V. cholerae
provides a protective barrier that insulates these organisms from the
action of numerous antibiotics [13]. Inhibition of LPS biosynthesis,
leading to a truncated LPS molecule, is a strategy for antibacterial
drug development in which this vital cellular structure is weakened
[13]. We therefore investigated the lipopolysaccharide biosynthesis,
D-alanine metabolism and peptidoglycan biosynthetic pathway.
2.5.1. Lipopolysaccharides (LPS) biosynthesis
Lipopolysaccharides are essential constituent of bacterial endotoxin
and deﬁne many of the properties of host–parasite interaction. Disrup-
tion of early catalytic steps in the biosynthesis of the lipid A through
chemical disruption by small-molecule inhibitors of LPS biosynthesis
has the potential to be developed into antimicrobial agents themselves
or as codrug formulations with antibiotics. Despite this promise, there
have been relatively few forays into the development of inhibitors of
LPS biosynthetic enzymes, with the exception of the lipid A biosynthetic
enzyme LpxC [14–16].
In our study we predicted LpxA, LpxB, LpxD and LpxC from LPS
biosynthesis pathway as the non-homologous essential proteins that
can be selected for novel antibacterial drug discovery. Lipid A biosynthe-
sis occurs in the cytoplasm on the cytosolic surface of the inner
membrane and it is catalyzed by nine unique enzymes [17]. The ﬁrst
three enzymes (LpxA, LpxC, and LpxD) in the pathway are essential
for lipid A biosynthesis and share no sequence or structural homology
with any mammalian proteins [18]. We report 2-hydroxymethyl-6-
octylsulfanyl-tetrahydro-pyran-3, 4, 5-triol to be an inhibitor of LpxA
enzyme in our study through druggability test. UDP-GlcNAc acyltrans-
ferase (LpxA) catalyzes the ﬁrst step of lipid A biosynthesis, the transfer
of the R-3-hydroxyacyl chain from R-3-hydroxyacyl acyl carrier
protein (ACP) to the glucosamine 3-OH group of UDP-GlcNAc [18].
Similarly gmhA encoding enzymes, phosphoheptose isomerase wasalso predicted to be an important therapeutic candidate in the
druggability test. The gmhA encoding enzyme is an isomerase which
is responsible for biosynthesis of the nucleotide-activated heptose pre-
cursors for the inner core assembly. It has been reported in the previous
study that defects in the biosynthesis of heptoses results in a dramatic
reduction of virulence and increased antibiotic susceptibility in bacteria
[19].
2.5.2. Peptidoglycan biosynthesis
Enzymes from peptidoglycan biosynthesis pathway such as MurA,
MurB, MurC, MurG and MurE form good drug target candidates [20].
The peptidoglycan layer of the cell wall serves as a base for lipid-rich
capsule. Peptidoglycan or murein is the polymeric mesh of the bacterial
cell wall, which plays a critical role in protecting the bacteria against
osmotic lysis. Most of the antimicrobial target, steps in the later stage
of cell wall biosynthesis. The earlier step in cell wall biosynthesis has
not been targeted. To date, only fosfomycin, which targets MurA (NAG
enolpyruvate transferase), has been developed as an antibacterial
agent [21]. So as a case study, we selectedMurA enzyme and performed
homologymodeling andmolecular docking simulation study. MurA en-
zyme is highly conserved across both Gram-positive andGram-negative
bacteria, is essential for cell survival and has no human homolog [22].
2.5.3. MurA ligase —a potential broad spectrum target
The Mur enzymes of the peptidoglycan biosynthesis pathway
constitute the ideal targets for the design of new classes of antimicrobial
inhibitors. MurA ligase of V. cholerae is a 44686 Da protein (UniprotKB
entry Q9KP62) of 419 amino acids in length, most likely expressed in
the cytoplasm. Based on sequence analysis and similarity with homolo-
gous enzymes (such as MurA ligase of V. ﬁscheri−87% identity), this
enzyme is deduced to have amino acid ligase activity, and is believed
to be involved in cellular processes like cell cycle, cell division, cell
wall organization, and peptidoglycan biosynthesis process.
2.5.4. Homology modeling of MurA ligase
Since the structure of V. cholerae MurA ligase has not been deter-
mined experimentally, homology modeling was used to construct a
three-dimensional model of the protein. A BLASTP search against the
PDB database revealed MurA chain A from V. ﬁscheri in complex with
substrate UDP-N-acetylglucosamine and the drug fosfomycin (PDB ID:
3VCY) as the closest homolog, with 87% identity and 99% query cover-
age (e-value = 0.0). Hence, the V. ﬁscheri protein was used as template
for homology modeling. The alignment of the target and template
sequences was generated by using the online program Multalin [23]
as shown in Fig. 2. Then the model of MurA ligase was built by
Modeller9v12 [24] and using the crystal structure coordinates of the
template structure (3VCY). The modeler program uses the spatial
constraints determined from the crystal structure, to build a three-
dimensional model of target protein with the unknown tertiary struc-
ture. The quality of the model with lowest DOPE (Discrete Optimized
Protein Energy) score (−50926.24) was then validated with the
PROCHECK [25], ERRAT [26] and Verify3D [27] programs, available at
the SAVES server. Ramachandran plot generated by PROCHECK for the
best model (Fig. S1) shows that not a single residue in the generated
structure falls in the disallowed region of the phi–psi dihedral angle
plot, while 96.4% residue fall in themost favored region, thus validating
the quality of themodel. The ERRAT server gives the overall quality fac-
tor (expressed as the percentage of the protein for which the calculated
error values fall in the 95% rejection limit) of the model as 88.078.The
main chain parameter plots for the model were generated using
PROCHECK shown in the (Fig. S2).The plots are for the Ramachandran
plot quality, peptide bond planarity, bad non-bonded interactions,
C-alpha tetrahedral distortion, main chain hydrogen bond energy
and the overall G-factor.
Fig. 3 shows the modeled structure of the MurA ligase protein of
V. cholerae with active site residues. Further, the template crystal
Table 1
Non-homologous essential proteins of V. cholerae identiﬁed from unique pathways with reference to humans as potential drug and vaccine targets. The sub-cellular localizations are based on the consensus results through predictions made by the
CELLO and PSORTb.
S.no. Non homologous essential protein targets from unique pathways Associated metabolic pathways Uniprot ID Length Molecular weight
(in kDa)
Trans-membrane
domain
PDB ID Mod-base
models
Sub-cellular
localization
1 alr,alanine racemase D-Alanine metabolism Q9KSE5 392 aa 42.498 0 no yes Cytoplasmic
2 ddl,D-alanyl-alanine synthetase A D-Alanine metabolism Q9KM17 334 aa 37.318 0 no yes Cytoplasmic
Peptidoglycan biosynthesis
3 UDP-N-acetylglucosamine acyltransferase/lpxA Lipo-polysaccharide biosynthesis Q9KPW4 262aa 28.494 0 no yes Cytoplasmic
4 lpxD, UDP-3-O-[3-hydroxymyristoyl] glucosamine N-acyltransferase Lipo-polysaccharide biosynthesis Q9KPW2 351aa 37.01 0 no yes Cytoplasmic
5 UDP-2,3-diacylglucosamine hydrolase Lipo-polysaccharide biosynthesis Q9KQZ7 242aa 28.031 0 no yes Cytoplasmic
6 lpxB, lipid-A-disaccharide synthase Lipo-polysaccharide biosynthesis Q9KPW5 379aa 42.25 0 no yes Cytoplasmic
7 lpxK, tetraacyldisaccharide 4′-kinase Lipo-polysaccharide biosynthesis Q9KQX0 336aa 37.127 1 no no Cytoplasmic
8 kdsA,2-dehydro-3-deoxyphosphooctonate, aldolase/kdsA Lipo-polysaccharide biosynthesis Q9KQ29 283aa 30.773 0 no yes Cytoplasmic
9 kdkA,3-deoxy-D-manno-octulosonic-acid kinase Lipo-polysaccharide biosynthesis Q9KVB9 235aa 27.408 0 no yes Cytoplasmic
10 gmhA, phosphoheptose isomerase Lipo-polysaccharide biosynthesis Q9KPY2 191aa 20.646 0 no yes Cytoplasmic
11 D; K03273 D-glycero-D-manno-heptose 1,7-bisphosphate phosphatase Lipo-polysaccharide biosynthesis Q9KTJ4 186aa 20.828 0 no yes Cytoplasmic
12 murA;UDP-N-acetylglucosamine, 1-carboxyvinyltransferase Amino sugar and nucleotide sugar
metabolism
Q9KP62 419aa 44.686 0 no yes Cytoplasmic
Peptidoglycan biosynthesis
13 murB, UDP-N-acetylenolpyruvoylglucosamine reductase Amino sugar and nucleotide sugar
metabolism
Q9KV40 347aa 38.27 0 yes yes Cytoplasmic
Peptidoglycan biosynthesis
14 murC, UDP-N-acetylmuramate–L-alanine ligase D-Glutamine and D-glutamate metabo-
lism
Q9KPG8 486aa 53.041 0 no yes Cytoplasmic
Peptidoglycan biosynthesis
15 UDP-N-acetylmuramoylalanyl-D-glutamyl-2,6-diamino-pimelate–
D-alanyl-D-alanyl ligase
Lysine biosynthesis Q9KPG3 453aa 47.931 0 no yes Cytoplasmic
Peptidoglycan biosynthesis
16 mraY, phospho-N-acetylmuramoyl-pentapeptide-transferase Peptidoglycan biosynthesis Q9KPG4 360aa 39.819 10 no no Membrane
17 murG; undecaprenyldiphospho-muramoylpentapeptide beta-N-
acetylglucosaminyltransferase
Peptidoglycan biosynthesis Q9KPG7 354aa 37.983 0 no yes Cytoplasmic
18 MviN protein Peptidoglycan biosynthesis O34238 525aa 57.153 12 no no Membrane
19 penicillin-binding protein 2 Peptidoglycan biosynthesis Q9KTF2 638aa 72.015 1 no yes Membrane
20 ﬂavodoxin ﬂdA Nitrogen metabolism Q9KQA1 175aa 19.782 0 no yes Cytoplasmic
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21 dnaA, chromosomal replication initiation protein Two-component system Q9KVX6 467aa 52.886 0 no yes Cytoplasmic
22 carbon storage regulator, CsrA Two-component system Q9KUH3 65aa 7.055 0 no no Cytoplasmic
23 nitrogen regulatory protein P-II Two-component system Q9KPX3 114aa 12.729 0 no yes Cytoplasmic
24 citrate lyase subunit gamma Citrate cycle (TCA cycle) Q9KTU1 98aa 10.768 0 no no Cytoplasmic
Two-component system
S.no. Non homologous essential gene targets from unique pathways Associated metabolic pathways Uniprot ID Length Molecular
weight(in kDa)
Transmembrane
domain
PDB ID ModBase
models
Sub-cellular
localization
25 cytochrome c oxidase, subunit ccoQ Oxidative phosphorylation Q9KS21 54aa 6.305 1 no no Cytoplasmic
Two-component system
26 ﬂiN, ﬂagellar motor switch protein Bacterial chemotaxis Q9KQ76 138aa 15.274 0 no yes Membrane
Flagellar assembly
27 motB, ﬂagellar motor protein MotB Bacterial chemotaxis Q9KTK9 318aa 35.393 1 no yes Membrane
Flagellar assembly
28 ﬂgL, ﬂagellar hook-associated protein FlgL Flagellar assembly Q9KQ17 397aa 44.943 0 no yes Extracellular
29 ﬂagellar protein FliO Flagellar assembly Q9KQ77 129aa 14.233 1 no no Membrane
30 phosphocarrier protein HPr Phosphotransferase system (PTS) Q9KTD6 85aa 9.109 0 no yes Cytoplasmic
31 PTS system, cellobiose-speciﬁc IIB, component Phosphotransferase system (PTS) Q9KSH5 101aa 11.148 0 no yes Cytoplasmic
32 phosphocarrier protein NPr Phosphotransferase system (PTS) Q9KP46 92aa 9.91 0 no yes Cytoplasmic
33 secY, preprotein translocase subunit secY Protein export P78283 444aa 48.663 10 no yes Membrane
Bacterial secretion system
34 secA, preprotein translocase subunit secA Protein export Q9KPH4 903aa 102.469 0 no yes Cytoplasmic
Bacterial secretion system
35 secE, preprotein translocase subunit secE Protein export Q9KV36 126aa 13.275 3 no no Membrane
Bacterial secretion system
36 secG, preprotein translocase subunit secG Protein export Q9KU83 111aa 11.482 2 no no Membrane
Bacterial secretion system
37 cholera toxin transcriptional activator Vibrio cholerae pathogenic cycle P15795 294aa 32.505 0 no yes Cytoplasmic
38 tcpE,toxin co-regulated pilus biosynthesis protein E Vibrio cholerae infection P0C6C9 340aa 38.068 3 no no Membrane
Vibrio cholerae pathogenic cycle
39 tcpF,toxin co-regulated pilus biosynthesis protein F Vibrio cholerae infection P0C6Q5 338aa 38.21 0 yes no Membrane
Vibrio cholerae pathogenic cycle
40 cholera enterotoxin, B subunit Vibrio cholerae infection P01556 124aa 13.957 0 yes no Cytoplasmic
Vibrio cholerae pathogenic cycle
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Fig. 2. Sequence alignment formodeling: Alignment of the V. choleraeMurA ligase protein sequence (UniprotKB entry Q9KP62)with template sequence, Vibrio ﬁscheriMurA ligase chain A
(PDB ID 3VCY) using Multialin.
88 P. Chawley et al. / Genomics 103 (2014) 83–93structure, 3VCY, was superimposed on the generated model using the
Pymol visualization software [28]. Both the structures were found to
be signiﬁcantly similar in topology, and aligned well with each other,
with an RMS value of 0.161 Å. The low overall RMSD reﬂects the high
structural conservation making it a good system for homology model-
ing. Through this assessment and analysis process, it is concluded that
the V. cholerae MurA model generated in the present study is reliable
to characterize protein–substrate and protein–ligand interactions and
to investigate the relation between the structure and function.
The active site of the protein model, where the reaction to be
inhibited takes place, was determined for docking studies. Since no
experimental data is available for MurA enzyme, the active site residues
of the closest homolog, the V. ﬁscheri protein (PDB ID: 3VCY)were used.
The corresponding residues were located in our model and assumed to
be a part of the catalytic site of our protein, since both the proteins share
high identity, are evolutionarily related, and have the same catalytic
function. The residues which are a part of the active site in our model
structure are Lys 23, Arg 92, Cys 116, Arg 121, Arg 398.
2.5.5. Docking
The putative active site residues of V. cholerae MurA protein were
picked to generate a grid in the centroid of the residues for virtual
screening. The experimental small molecules screened from theFig. 3. Homology model: Vibrio choleraeMurA model generated by Modeller9V12. Active site
sheets.Drug Bank database were docked with MurA ligase protein model
using GLIDE module of Schrodinger [29]. The GLIDE XP docking score
(−13.719 kcal/mol) and the Glide Emodel score (−109.126) of the
Uridine-Diphosphate-N-Acetyl glucosamine (DB03397), the substrate
of MurA enzyme were signiﬁcantly high (Table 2). Docking pose analy-
sis shows numerous hydrogen bond interactions with the amino acid
residues of the protein, many of which were with amino acids that are
part of the putative active site Arg 121, Arg 92, and Lys 23 as shown in
Fig. 4.
The next favorable interaction is shown by 3′-1-Carboxy-1-
Phosphonooxy-Ethoxy-Uridine-Diphosphate-N-Acetylglucosamanine
(tetrahedral intermediate of MurA enzyme) with XP score −
13.581 kcal/mol and having hydrogen bond interaction with the active
site residuesArg 398, Arg 121, Lys 23(Fig. S3(d)). These twonatural inhib-
itors shared the same structural backbone. Fosfomycin, which is a natural
product antimicrobial agent for MurA enzyme [30], is also identiﬁed as
the as a therapeuticmolecule in the druggability test. When this inhibitor
was docked againstV. choleraeMurA ligasemodel, itwas found to have an
XP score of−6.565 kcal/mol and an Emodel score of 0.000 kcal/mol. The
antibiotic showed two hydrogen bond interaction with the active site
residues Arg 121 and Arg 92. Fosfomycin inactivates the enzyme by
irreversibly binding to the enzyme forming a covalent adducts with the
cysteine 115 residues of E. coliMurA [30].residues are labeled and numbered, coils represent α-helices, and arrows represent beta-
89P. Chawley et al. / Genomics 103 (2014) 83–93The docking pose of the other screened compounds had good XP
score with hydrogen bond interaction with key active site residues
(Table 2). Interestingly these molecules are structurally different from
each other. The result from the docking study presents an interesting
opportunity for the structure-based design of small-molecule inhibitor
of MurA against the recent fosfomycin resistant strains. As a test
study, we referred to the previous work in an opportunist bacterial
pathogen Acinetobacter baumannii where the model building and lead
inhibitor identiﬁcation were carried out on two essential gene targets,
MurA and MurB enzyme. Compounds showing activity against MurA
enzyme of other organisms were collected from literature and were
docked to the active site residues of the homology model of MurA
enzyme by GLIDE software [31]. The inhibitors showed hydrogen
bond interaction with the same active site residues such as Lys 22, Arg
398 and Arg 92, as in our case. This test study data is a validation of
the docking protocol followed in our system.
2.5.6. D-alanine metabolism
The D-alanine-D-alanine ligase “ddlA” and the alanine racemase
“alr” from this pathway have no similarity to any of the host proteins.
D-Alanine is a necessary precursor in the bacterial peptidoglycan bio-
synthetic pathway. The naturally occurring L-isomer is racemized to
its D-form through the action of a class of enzymes called alanine
racemase. These enzymes are ubiquitous among prokaryotes and are
absent in eukaryoteswith a fewexceptionsmaking them a logical target
for the development of antibiotics. Alanine racemase “alr” has in fact
been identiﬁed as a target by our approach as indicated in Table 1. In
V. cholerae, a dedicated racemase produced D-Met and D-Leu [32]. In
our study we identiﬁed one alanine racemase inhibitor, the structural
D-alanine analogue D-cycloserine, an FDA approved molecule in the
druggability test. Designing of inhibitors against the key enzymes in
peptidoglycan biosynthesis signiﬁcantly weakens the structural integri-
ty of the cell wall and leads to osmotic lysis [33].
2.6. Targets from other pathways
2.6.1. Bacterial chemotaxis
A membrane protein, ﬂagellar motor protein; product of motB gene
is known to aid bacterial chemotaxis and ﬂagellar assembly that can be
regarded as a good vaccine target. Themotility protein B (MotB) is a key
component of the bacterial ﬂagellar motor. It anchors the MotA/MotB
stator ring of the motor to peptidoglycan of the cell wall and forms
part of the proton-conducting channel that couples proton ﬂow for
generation of the turning force [34]. The motility and chemotaxis are
believed to guide V. cholerae to its preferred colonization site within
the small intestine for establishment of infection.
2.6.2. Bacterial secretion system
Membrane proteins such as secG, secY and secE identiﬁed from
bacterial secretion systemand protein export are a fewother candidates
excellent for vaccine design. These preprototein translocase subunits
are part of the V. cholerae Sec pathway. SecY, SecE, and SecG form an
essential heterotrimeric protein complex that is central to the SecTable 2
Docking scores and hydrogen bond interactions between protein residues of MurA enzyme an
Drug bank XP score (kcal/mol) Glide energy
DB00828 (Fosfomycin) −6.565 −25.517
DB01679 (Propyl Trihydrogen Diphosphate) −8.421 −75.590
DB03089 (L-iso-aspartate) −7.953 −20.132
DB03397 (Uridine-Diphosphate-N-Acetylglucosamine) −13.719 −72.324
DB04174 (3′-1-Carboxy-1-Phosphonooxy-Ethoxy-
Uridine- Diphosphate-N-Acetylglucosamine)
−13.581 −73.561
DB04474 (1-Anilino-8-Naphthalene Sulfonate) −7.555 −33.009
a Indicates the residue in bold are part of the putative active site of the protein.pathway. This SecYEG complex serves as a transport channel for the
movement of protein synthesized in the cytoplasm to the extra cyto-
plasmic environment. These transport and movement of protein
through the SecYEG channel are regulated by cytoplasmic ATPase
SecA, via repeated cycles of ATP-binding and hydrolysis. It has been ob-
served that disruption of SecYEG-SecA leads to aggregation of unfolded
bacterial proteins in the cytoplasm and triggers a cellular stress
response [6]. Therefore, following the biological signiﬁcance and
increasing evidence supporting the therapeutic potential of protein ex-
port machinery, we suggest that the development of inhibitors against
these proteins holds great therapeutic potential for the treatment of
V. cholerae infections. However, one important criterion that must be
met so that membrane protein can be a successful vaccine candidate is
that the protein must possess surface-exposed and antibody accessible
antigenic determinants. All the membrane proteins selected are identi-
ﬁed for antigenic peptide epitopes and their binding interaction with
MHC class I. Interaction ofMHCClass I presented antigenswith cytotox-
ic CD8+ lymphocytes is one of the potential vaccine induced immune
responses and thus, these membrane proteins fulﬁll the prerequisite
of being potent vaccine candidates.
2.6.3. V. cholerae infection
Among the other candidate drug target, Cholera endotoxin B subunit
from V. cholerae pathogenic cycle is predicted to be a therapeutic
candidate in our study with three dimensional structures available at
PDB. The druggability test revealed an experimental small molecule 3-
Amino-4-{3-[2-(2-Propoxy-Ethoxy)-Ethoxy]-Propylamino}-Cyclobut-
3-Ene-1, 2-Dione (DB03077) as an inhibitor of the predicted drug target
(Table S4).
3. Discussion
The search for drug targets using computational methods and inte-
grated ‘omics’ data, such as genomics, proteomics, and metabolomics,
has received much attention and has been increasing continuously
[35].Computational genomic approaches have already facilitated the
search for potential drug targets against many pathogens [36,37].The
present study is the ﬁrst computational analysis of KEGG annotated
metabolic pathways that led to identiﬁcation of several proteins for
effective drug design and vaccine development against V. cholerae.
The possibilities of selecting targets using computational approaches
with integrated ‘omics’ data rely on searching for those genes/proteins
that are absent in the host and/or non-homologous to the host
proteome but present in the pathogen as designing a drug speciﬁc to
such targets will have an effect only on the pathogen and not any
other aspect of the host biology [36].This promoted us to search non-
homologous proteins of the pathogen against the human proteome
and resulted in the identiﬁcation of 264 proteins of V. cholerae which
represent no signiﬁcant homology.
The potential of the identiﬁed non-homologous proteins to be a
therapeutic target of a given pathogen gene product is dependent on
two broad types of information. First, the role of the gene in the growth
and survival of the pathogen deﬁning the essentiality of genes/proteinsd ligands as determined after docking by Glide.
Glide Emodel H-bond interacting residuesa Drug type
0.000 Arg121, Arg92, His126 Approved
−106.414 Lys23, Arg92, Arg121, His126, Ser163, Gly165 Experimental
−24.200 Arg121, Arg332, Lys23, Arg398 Experimental
−109.126 Arg121, Val162, Ile328, Ala120, Arg92, Asp50, Lys23,
Asn24, His126, Val164
Experimental
0.000 Arg398, Arg121, Gly165, Asp124, Pro122, Ile328,
His126, Asn24, Lys23
Experimental
−46.127 Arg92, His126, Arg121 Experimental
Fig. 4. Lig-plot of MurA with Uridine-Diphosphate-N-Acetyl glucosamine (DB03397). Oxygen (O), Nitrogen (N) and Carbon (C) atoms are represented in red blue and black circles.
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modulates that target into a drug deﬁning the druggability of the target
proteins [38]. There have been several attempts to deﬁne or predict
essential genes in infectious agents through systematic disruption of
candidate genes and transposon mutagenesis. However, for the vast
majority of infectious organisms, high throughput experimental
interrogation of essentiality is currently not possible, and efforts to
deﬁne essentiality have been based on bioinformatics predictions. In
this studywemade an attempt to predict the non-homologous essential
proteins of V. cholerae following a similar fashion based on bioinformat-
ics predictions through homology search with the already identiﬁed
essential gene/protein database from 22 bacteria in the DEG.
Advances in genome sequencing, bioinformatics and cheminformatics
coupled with experimental data have shown several additional factors
such as molecular mass (b110 kDa), sub-cellular localization, whether
the protein is transmembrane and availability of 3D structural informa-
tion that can aid in determining the suitability of therapeutic targets
besides identifying the proteins of the pathogen as non-homologous
and essential proteins [38]. Proteins with smaller molecular mass were
found very likely to be soluble and easier to purify [39]. In our study wefound, all the 29 cytoplasmic proteins have a molecular weight less than
110 kDa. Apart from the molecular weight, knowledge about the sub
cellular localization of proteins will help to understand the function and
can lead to important therapeutics and diagnosis [40]. The membrane
localization of 11 proteins from the non-homologous essential proteins
identiﬁed using CELLO server was in line with the prediction of trans-
membrane domain by TMHMMserver except ﬂagellarmotor switch pro-
tein and toxin co-regulated pilus biosynthesis protein F (Table 1). They
are regarded as potential vaccine candidates for development of effective
vaccine asmany of the vaccines that protect by eliciting antibodymediat-
ed immunity that appears to be secreted toxins and/or highly expressed,
surface exposed molecules [41].The present comparative genomics
approach will help to conduct biological assays by substantially reducing
the number of proteins to be tested.
Although V. cholerae is a most widely studied pathogenic bacteria, the
availability of very fewnon-homologous essential protein structure of the
pathogen, demarcates skewedness of research areas in V. cholerae. The
structural information on protein helps to increase the druggability
value by facilitating a structure-based drug design, including homology
modeling, docking, virtual screening or pharmacophore-based screening.
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protein to be a therapeutic target, the druggability of the protein, was
determined with the homology search against the Drug Bank target
proteins. The search reduces the testable proteins to 16 that produce a
list of different types of drugs in the Drug Bank that bind to proteins of
the pathogen. However, the protein sequence similarity search had
limitations in that it does not assure the structure or binding pocket
congruency with the identiﬁed similar proteins.
From the several proteins identiﬁed in different unique pathway;we
found proteins from bacterial secretion system as vaccine and drug
targets. Speciﬁc example may include the preprototein translocase
subunits (secG, secY and secE). These pathways are critical for growth
and survival of the bacteria. Similarly peptidoglycan is the major struc-
tural component of the cell wall in Gram-positive and Gram-negative
bacteria. Peptidoglycan is a macromolecule consisting of long amino-
sugar strands cross-linked by short polypeptide chain which plays a
critical role in bacteria against osmotic lysis. MurA enzyme which
catalyzes the ﬁrst committed step of bacterial peptidoglycan biosynthe-
sis is a prime candidate for therapeutic intervention.
Homology modeling followed by molecular docking study of the
screened molecules from the Drug Bank library revealed that the
docking score of Uridine-Diphosphate-N-Acetyl glucosamine is fared
better. The molecule may act as a competitive inhibitor based on the
structure, and should be tested in vivo, and that further analogs could
be generated based on the molecules discovered here. Computational
studies like these can provide a rapid approach to identify novel drug
targets and develop better drugs against crucial pathogens.
In summary using the computational comparative and subtractive
genomic study several proteins in the V. cholerae genome have been
identiﬁed that can be targeted for effective drug design and vaccine
development. Asmany of the identiﬁed drug targets have been reported
to play a role in the critical metabolic pathways that regulate bacterial
pathogenicity and essential nutrient uptake, a systematic approach to
develop drugs against these targets would likely be very promising for
the treatment of cholera. This information can lead to signiﬁcant
progress in testing the efﬁcacy of already available antibiotics, in
comparison with novel drug development, equally important but
more time consuming. It is expected that the drugs developed against
identiﬁed targets will be speciﬁc to the pathogen and of minimal
toxicity for the host.
4. Materials and methods
4.1. Identiﬁcation of host and pathogen metabolic pathways
Through a systematic work ﬂow, this is the ﬁrst computational and
subtractive genomics analysis of different metabolic pathways for the
identiﬁcation of potential drug and vaccine targets in the V. cholerae
O1 biovar El Tor N16961 genome (Fig. 1). We referred to the previous
work on comparative/subtractive genomicsworkﬂow [5,6]. For deriving
metabolic pathway based information, we used Kyoto Encyclopedia of
Genes and Genomes (KEGG) [42].We extracted the data with reference
to the metabolic pathways and identiﬁcation numbers for the human
host and the pathogen and saved them locally. After that, a manual
comparison was conducted by searching the name of each individual
pathway of V. cholerae against 276 pathways of the host, H. sapiens
and the pathway that did not appear in the host but was present in
the pathogen, was selected and considered as unique to V. cholerae.
The remaining pathways were listed as common pathways (Table S1).
We obtained the proteins and the corresponding amino acid sequences
from the Swiss-Prot database [43].
4.2. Identiﬁcation of non-homologous and essential pathogen proteins
In the beginning of search, proteins from both the unique and com-
mon pathways were subjected to BLASTP analysis [44]. We restrictedour search to human proteins through the ‘select organism’ option
available under BLASTP parameters. We classiﬁed proteins as non-
homologous if they did not have hits below the e-value threshold of
0.005. The criterion for selection-value was based on previous studies
[5,6,12,35]. In the second step of our ﬁltering process, all the non-
homologous proteins were further ﬁltered based on the essentiality
criteria for V. cholerae. These essential proteins are necessary for growth
and replication and therefore form attractive targets for antimicrobial
treatments. We referred to the Database of Essential Genes (DEG) [8]
for generating information about essential proteins of V. cholerae. Filter-
ing criteria such as e-value cut-off of 10−10 and a minimum bit score of
100 were used for screening the non-homologous essential proteins of
the pathogen. For setting the e-value we referred to the previous work
[5,6].
4.3. Drug target prioritization
There are certain criteria that help in determining suitable drug
targets which were evaluated for each of the potential drug targets.
This involved calculation of molecular weight (MW) using computa-
tional tools and drug targets associated literature available at Swiss-
Prot database. Transmembrane predictions were made by TMHMM
server [11], and we searched for the presence of solved 3D structures
through Protein Data Bank (PDB) [45] and Mod-Base [46]. Additionally,
the membrane proteins were analyzed for MAPPP (MHC-I Antigenic
Peptide Processing Prediction) (/http://www.mpiib-berlin.mpg.de/
MAPPP/) with the SYFPEITHY matrix which combines existing predic-
tion tools for proteosomal processing and MHC class I anchoring.
Druggability is another important target prioritization criterion,
which is deﬁned as the likelihood of being able to modulate the activity
of the protein target with a small-molecule drug [47]. The druggability
potential of each of the identiﬁed drug targets was calculated bymining
theDrugBank contents. TheDrugBankdatabase is a unique bioinformat-
ics and chemo-informatics resource that combines detailed drug
(i.e. chemical, pharmacological and pharmaceutical) data with compre-
hensive drug target (i.e. sequence, structure, and pathway) information
[48].The database contains 6811 drug entries including 1528 FDA-
approved small molecule drugs, 150 FDA-approved biotech (protein/
peptide) drugs, 87 nutraceuticals and 5080 experimental drugs.
Additionally, 4294 non-redundant protein (i.e. drug target/enzyme/
transporter/carrier) sequences are linked to these drug entries. The
default parameters for BLASTP were used to line up the potential drug
targets from V. cholerae against the list of protein targets of compounds
found within the Drug Bank. The selection criteria on BLASTP results is
based on previous study [49], that is alignments with e-values less
signiﬁcant than 1 × 10−25 were removed.
4.4. Homology modeling
A homology model for UDP-N-acetyl glucosamine 1-carboxyvinyl
transferase (MurA) of V. cholerae was built using MODELLER (9v12)
programme [24]. A BLASTP search of the V. cholerae MurA sequence
against the proteins available in the PDB database was carried out.
Based on the sequence identity and query coverage, MurA ligase from
V. ﬁscheri (PDB ID: 3VCY) was chosen as the most suitable template for
homology modeling. The primary sequences of the two proteins were
aligned using theMultalin program. The quality of themodelwas veriﬁed
using PROCHECK, a protein structure veriﬁcation program. The model
was used for molecular docking study.
4.5. Docking study
The molecules which passed the druggability test from the
Drug Bank database were selected for docking study to determine the
molecular interaction in the enzyme active site.
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The three dimensional structure model of MurA enzyme of
V. cholerae was prepared for small molecule docking using the Protein
Preparation Wizard module of Schrodinger Software Suite 2010. The
program removes all of water molecules, adds hydrogen atoms to the
protein structure and assigns all of atom force ﬁeld (OPSL-2005)
charges and atom types. Minimizations were performed until the aver-
age root mean square deviation of non-hydrogen atoms reached 0.3 Å.
4.5.2. Ligand data and preparation
The small molecules from the Drug Bank database which passed the
druggability test were prepared using the LigPrep module [50]. In total,
sixmolecules were identiﬁed in the search, which includes the antibiot-
ic fosfomycin and the natural substrate Uridine-Diphosphate-N-
Acetylglucosamine. LigPrep is a utility of Schrodinger software suit
that combines tools for generating 3D structures from 1D (Smiles)
and 2D (SDF) representation, searching for tautomers and steric
isomers and performs a geometry minimization of ligands. The
ligands were minimized by means of Molecular Mechanics Force Fields
(OPLS-2005) [51] with default setting.
4.5.3. Docking protocol
The prepared ligandswere docked into the active site of MurA ligase
using the GLIDE (Grid-based LIgand Docking with Energetics) module
[29] of Schrodinger. Since the binding side or active site residues of
the V. choleraeMurA ligase are not known experimentally, so the cata-
lytic residues of the V. ﬁscheriMurA enzymewere located in our protein
model and used for receptor grid generation. The ligands were docked
initially using the ‘standard precision’ method. Glide Score is used to
predict binding afﬁnity and rank the ligands in database screens,
while a composite scoring function Emodel, which is a combination of
energy-grid score, binding afﬁnity predicted by Glide Score and internal
strain energy (for ﬂexible docking) for the model is used to select the
correctly docked pose. The ligand with the best SP docking scores was
then further analyzed by eXtra Precision (XP) docking.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ygeno.2013.12.002.
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